OncLive.com
@OncLive
Followers
49K
Following
11K
Media
23K
Statuses
116K
Healthcare publisher of oncology focused articles, videos, panel discussions, and much more that run the gamut of oncology care and management.
New Jersey, USA
Joined May 2009
We're passing the phone to @CParkMD of @UofL and the guests of the @OncLive News Network: On Location at @ASH_hematology! Check back today for insights on #leusm #lymsm #mmsm and more ✨ #ASH25 @drghildebrandt @MMBaljevicMD @JoshuaBrodyMD @JavierPinillaMD
https://t.co/10dbsurWZB
2
3
12
At ASH 2025, oral decitabine/cedazuridine plus venetoclax drove early, deep responses in treatment-naive HR-MDS and CMML, achieving a 91% ORR with encouraging survival outcomes. 🔬 Read more: https://t.co/OizhEAoxK2
#MDS
0
1
1
Long-term follow-up from the BGB-3111-LTE1 study shows zanubrutinib delivers durable PFS in R/R CLL/SLL, with median PFS exceeding 5 years after COVID-19 adjustment. Data presented at ASH 2025. 🔬 Read more: https://t.co/XaTAKHSrIq
#CLL #ASH25
onclive.com
Zanubrutinib displayed long-term PFS and responses in patients with relapsed/refractory CLL/SLL.
0
1
3
Higher response rates and encouraging early PFS signals. ASH 2025 results from BRUIN CLL-314 suggest pirtobrutinib may reshape first-line and R/R CLL/SLL treatment. 🩸 Read the analysis: https://t.co/lHVTNcHzx5
#CLL
onclive.com
Pirtobrutinib yeilds superior overall response rates and promising progression-free survival compared to ibrutinib in chronic lymphocytic leukemia.
0
1
2
🔬 First-in-human results for KLN-1010 in R/R myeloma have shown sustained MRD-negativity and CAR T-cell expansion in patients, sending encouraging early signals for the agent. Read more here ⚛️: https://t.co/JOmH68a9Ia
#mmsm #ASH25 #oncology
onclive.com
The in vivo, BCMA-directed CAR T-cell therapy produced initial MRD-negative responses and persistent CAR T-cell expansion in 4 patients with relapsed/refractory myeloma.
0
3
5
📈 The ASCENT-03 trial has shown increased QOL benefits for sacituzumab govitecan vs chemotherapy in TNBC, complimenting previous trial data and supporting a potential shift in standard of care. Read more here 👀: https://t.co/6TSDiHGrzD
#bcsm #SABCS25 #oncology
onclive.com
PRO data from ASCENT-03 showed that the mean change in physical functioning from baseline to week 25 favored sacituzumab govitecan over chemotherapy.
0
3
19
This week’s #OncFive 5⃣: ✅ @US_FDA clears T-DXd combo in HER2+ breast cancer 💉 SC amivantamab approved for EGFR+ NSCLC 🧬 Rucaparib cleared in BRCA+ mCRPC 🏆 Priority voucher for teclistamab combo in myeloma 🚻 Periop EV combo meets EFS/OS in MIBC 🔗: https://t.co/u6ZwSm8WlN
0
2
6
Analysis Sheds Light on Dosing Patterns of Ponatinib in Patients With CP-CML in the United States @GCC_Cortes @GACancerCenter @ASH_hematology #ASH25 #leusm #medtwitter #oncology
onclive.com
Only 13% of US patients with CP-CML received FDA-recommended ponatinib dosing, highlighting gaps in dose optimization and the need for education.
0
0
5
👀 SEQUOIA trial has shown impressive long-term PFS data for zanubrutinib and venetoclax in CLL and SLL, building the confidence of trial investigators for the regimen. Read more here 📈: https://t.co/x9RMSbIdhi
#leusm #ASH25 #oncology
onclive.com
Zanubrutinib plus venetoclax maintained a 36-month PFS rate of 87% (95% CI, 78.6%–92.4%) in treatment-naive CLL/SLL.
0
1
0
ctDNA at end of treatment may refine risk stratification in lymphoma. ASH 2025 findings link MRD negativity with prolonged EFS and highlight ctDNA as a tool to clarify ambiguous imaging results. 🔍 Full details: https://t.co/qtYmc2mMr0
#LymphomaResearch #ASH25
0
0
0
New AGAVE-201 findings suggest axatilimab 0.6 mg/kg monthly is safe and feasible for patients with chronic GVHD, offering a less frequent dosing option after transition. 📊 Explore the data: https://t.co/N4y61xnYJk
#Hematology
onclive.com
The AGAVE-201 trial showed successful transition from axatilimab 0.3 mg/kg biweekly to 0.6 mg/kg monthly in cGVHD.
0
0
0
Updated phase 3 VERIFY data show rusfertide delivers sustained hematocrit control below 45% and high rates of phlebotomy ineligibility through week 52 in PV. Rapid responses followed placebo crossover. 🩸 Read more: https://t.co/qxe4C9lUmN
#PolycythemiaVera #ASH25
onclive.com
Rusfertide sustained hematocrit control and sharply reduced phlebotomy need through week 52 in PV, showing durable efficacy and a consistent safety profile.
1
1
7
Phase 3 COBRA interim results reinforce KRd as a compelling induction option in newly diagnosed multiple myeloma, with improved PFS, deeper responses, and less neuropathy vs VRd. 🧬 Read the analysis: https://t.co/gtf6GlvRRO
#MultipleMyeloma #ClinicalTrials
onclive.com
KRd improved PFS, deepened responses, and led to higher MRD negativity vs VRd in newly diagnosed multiple myeloma.
0
3
5
Durable responses ⏱️ In R/R CLL/SLL, lisaftoclax achieved a median duration of response of 18.5 months and 12-month PFS of 66.4% in a pivotal phase 2 study. Learn more: https://t.co/hWK0eGFw9N
#CLL #Hematology
0
1
4
🔬 No incidence of ziftomenib-related QTc prolongation and other encouraging safety data were shown for ziftomenib, venetoclax, and azacitidine in AML, helping the treatment be well tolerated and effective. Read more here 📰: https://t.co/qS7hS3LmGu
#leusm #ASH25 #oncology
onclive.com
Ziftomenib plus venetoclax and azacitidine was safe and effective in patients with relapsed/refractory AML harboring NPM1 mutations or KMT2A rearrangements.
0
2
8
From long-term follow-up to potential cure 📈 CARTITUDE-4 highlights low progression rates and sustained survival in standard-risk R/R myeloma treated with cilta-cel. See full coverage: https://t.co/uelOxFnpeC
#MultipleMyeloma #CAR_TCellTherapy
onclive.com
In the CARTITUDE-4 trial, 80.5% of patients with standard-risk multiple myeloma were progression-free at 2.5 years after receiving cilta-cel.
0
5
45
⏱️ Early CAR T pays off 🧬 CARTITUDE-1/4 analyses show earlier-line cilta-cel administration in R/R multiple myeloma yields stronger PFS and OS outcomes compared with later lines. Read more: https://t.co/G3FiNVVaWX
#MultipleMyeloma #CAR_T
onclive.com
Administering cilta-cel earlier in treatment improves clinical outcomes, with superior PFS and OS rates compared to later intervention.
0
1
3
⚛️ An ORR of 100% was shown for GLPG501 in patients with R/R MCL, in addition to other promising antitumor activity, encouraging researchers to further develop the treatment. Read more here 📈: https://t.co/XS7LMqvwlA
#lymsm #oncology #ASH25
onclive.com
GLPG5101 produced responses and had a manageable safety profile in relapsed/refractory non-Hodgkin lymphoma, including mantle cell lymphoma.
0
1
7
CRS and neurotoxicity were shown to be largely low, in addition to no TEAE-led discontinuations or death for MK-1045 therapies in B-cell ALL, making an encouraging safety profile for the treatment. ⚛️ Read more here 📰: https://t.co/tRvLMQrHb0
#leusm #ASH25 #oncology
onclive.com
The safety profile associated with MK-1045 administration was manageable with dose interruption and standard medical care.
0
0
4
Watch @Neil_Iyengar, @KalinskyKevin, and Virginia Borges, MD, discuss the current frontline treatment landscape for advanced triple-negative breast cancer and where the paradigm is heading. 💗📊 View more here:
onclive.com
Panelists discuss the current state of the frontline treatment paradigm for advanced triple-negative breast cancer
0
2
4
Following #ASH25, we asked experts to reflect on the top data and trends to emerge from the meeting in CML, CLL, B-cell lymphomas, and other hematologic malignancies.🩸 Unlock their exclusive insights in the recap below! 🔐👇: https://t.co/m65odw2rcg
@ASH_hematology #hematology
0
0
2